{"text": "An SRE was defined as a pathologic bone fracture ( vertebral and non - vertebral ) , spinal cord compression , radiation to bone , or surgery to bone .", "label": "", "metadata": {}, "score": "32.124825"}
{"text": "An SRE consists of any of the following : a pathologic fracture , the need for radiation or surgery to ameliorate bone pathology secondary to tumor growth , or spinal cord compression .", "label": "", "metadata": {}, "score": "35.71721"}
{"text": "Time to First Individual Type of SRE [ Time Frame : 52 weeks ] [ Designated as safety issue : No ] .Types of SREs analyzed were pathologic fractures ( vertebral and non - vertebral ) , spinal cord compression , radiation to bone and surgery to bone .", "label": "", "metadata": {}, "score": "37.682076"}
{"text": "In patients with skeletal metastases , the growing cancer cells weaken and destroy the bone around the tumor .This can result in a number of serious complications , collectively called SREs , comprising fracture , radiation to bone , surgery to bone or spinal cord compression .", "label": "", "metadata": {}, "score": "37.97652"}
{"text": "The primary endpoint was time to first on - study SRE .( i ) .Approximately 50 - 70 percent of cancer patients with bone metastases will experience debilitating SREs .", "label": "", "metadata": {}, "score": "38.45367"}
{"text": "For long - term pain relief , the time to progression was defined as the interval between the initial date of radiotherapy and the date when increased pain or increased dosage of the analgesic was first documented after the best pain relief response at treated sites .", "label": "", "metadata": {}, "score": "39.86338"}
{"text": "Approximately 50 - 70 percent of cancer patients with bone metastases will experience debilitating SREs .( ii ) ( iii ) ( iv ) Events considered to be SREs include fractures , spinal cord compression , and severe bone pain that may require surgery or radiation .", "label": "", "metadata": {}, "score": "44.811943"}
{"text": "Introduction .Patients with bone metastases from prostate cancer frequently experience skeletal morbidities as a result of their disease .Skeletal - related events ( SREs ) , such as pathological fractures and spinal cord compression , are major causes of morbidity in patients with prostate cancer and may lead to other comorbidities including pain [ 1 , 2 ] .", "label": "", "metadata": {}, "score": "46.354813"}
{"text": "However , these results indicate that conventional radiotherapy alone for pain relief may be inadequate for oligometastases and oligo - recurrence of bone in prostate cancer .", "label": "", "metadata": {}, "score": "47.60504"}
{"text": "We analyzed the overall survival and the effect of radiotherapy on pain relief and the incidence of SREs , including pathological fracture and spinal cord compression .", "label": "", "metadata": {}, "score": "49.593536"}
{"text": "If a patient had no SRE events , the entire study period was counted as \" time at risk \" .This SMR calculation method had the advantage of avoiding multiple counts of possibly interdependent SREs ( e.g. having 1 fracture increases the probability of having a subsequent SRE ) .", "label": "", "metadata": {}, "score": "49.741287"}
{"text": "( 1 ) With improvements in cancer care , including earlier diagnosis and new treatment options , leading to increases in survival rates(2 ) , the number of patients developing metastatic disease secondary to a primary cancer is increasing .", "label": "", "metadata": {}, "score": "50.969154"}
{"text": "Successful management of bone metastases during these periods is essential for reducing the skeletal complications and for maximizing patients ' quality of life .Therefore , we must carefully manage metastatic bone disease from an early stage in prostate cancer .", "label": "", "metadata": {}, "score": "51.265495"}
{"text": "( 2 ) With improvements in cancer care , including earlier diagnosis and new treatment options , leading to increases in survival rates(3 ) , the number of patients developing metastatic disease secondary to a primary cancer is increasing .", "label": "", "metadata": {}, "score": "51.47297"}
{"text": "( 2 ) With improvements in cancer care , including earlier diagnosis and new treatment options , leading to increases in survival rates(3 ) , the number of patients developing metastatic disease secondary to a primary cancer is increasing .", "label": "", "metadata": {}, "score": "51.47297"}
{"text": "The primary endpoint was to evaluate if denosumab is non - inferior to Zometa with respect to the first on - study skeletal related event ( SRE ) , measured using a composite endpoint of four SREs : fracture , radiation to bone , surgery to bone , or spinal cord compression .", "label": "", "metadata": {}, "score": "52.91015"}
{"text": "With bone metastases the growing cancer cells weaken and destroy the bone around the tumor .The damage the tumor has caused to the bone can result in a number of serious complications , collectively called SREs .", "label": "", "metadata": {}, "score": "53.366146"}
{"text": "With bone metastases the growing cancer cells weaken and destroy the bone around the tumor .The damage the tumor has caused to the bone can result in a number of serious complications , collectively called SREs .", "label": "", "metadata": {}, "score": "53.366146"}
{"text": "In clinical trials testing new medications for bone metastases , treatment success has been measured by whether the bone complications , or SREs , caused by the bone metastases are reduced or delayed .", "label": "", "metadata": {}, "score": "53.39908"}
{"text": "Approximately half of the lung cancer subgroup had an SRE prior to randomization , most often radiation to bone .Almost 90 % of the patients had received prior systemic cancer therapy .", "label": "", "metadata": {}, "score": "53.4647"}
{"text": "Overall survival was calculated as the time interval from the last day of radiotherapy for bone metastases to the time of death .Progression - free survival for bone pain was defined as the proportion of patients surviving with decreased pain from the onset of pain relief to pain relapse at a treated site .", "label": "", "metadata": {}, "score": "53.577297"}
{"text": "Previous studies showed that independent prognostic variables for survival among patients with prostate cancer were patient age , time to androgen - independent disease , the extent of metastatic disease , and number of metastases on bone scan [ 14 ] .", "label": "", "metadata": {}, "score": "53.979553"}
{"text": "In clinical trials testing new medications for bone metastases , treatment success has been measured by whether the bone complications , or SREs , caused by the tumor are reduced or delayed .", "label": "", "metadata": {}, "score": "54.22434"}
{"text": "In clinical trials testing new medications for bone metastases , treatment success has been measured by whether the bone complications , or SREs , caused by the tumor are reduced or delayed .", "label": "", "metadata": {}, "score": "54.22434"}
{"text": "In clinical trials testing new medications for bone metastases , treatment success has been measured by whether the bone complications , or SREs , caused by the tumor are reduced or delayed .", "label": "", "metadata": {}, "score": "54.22434"}
{"text": "[ 3 ] reported an analysis of survival in prostate cancer patients with bone metastases using a semiquantitative grading system based upon the extent of disease ( EOD ) on the bone scintigram .", "label": "", "metadata": {}, "score": "56.521084"}
{"text": "Our study has several limitations .There was also no control group , that is , one that did not receive radiotherapy .Therefore , in the future , a large prospective study is required to investigate the actual benefits , including overall survival associated with radiotherapy for oligometastases and oligo - recurrence of bone in prostate cancer .", "label": "", "metadata": {}, "score": "56.758453"}
{"text": "To our knowledge , no previous study has examined overall survival in this patient population .Although the widely accepted treatment for patients with metastatic prostate cancer is hormonal therapy , we should manage oligometastases , oligo - recurrence , and polymetastases separately because of their difference in prognosis .", "label": "", "metadata": {}, "score": "57.21611"}
{"text": "With bone metastases the growing cancer cells weaken and destroy the bone around the tumor .The damage the tumor has caused to the bone can result in a number of serious complications , collectively called skeletal related events ( SREs ) .", "label": "", "metadata": {}, "score": "57.416065"}
{"text": "Superiority was demonstrated with statistical significance for both delaying the time to the first on - study SREs ( fracture , radiation to bone , surgery to bone , or spinal cord compression ) and delaying the time to the first - and - subsequent SREs .", "label": "", "metadata": {}, "score": "57.856834"}
{"text": "Both pathological fractures and spinal cord compression with neurologic deficit negatively affect quality of life [ 22 ] .Moreover neurologic recovery is unlikely if spinal compression is not relieved within 24 - 48 hours [ 23 ] .", "label": "", "metadata": {}, "score": "59.12326"}
{"text": "All are serious complications for advanced cancer patients .The economic burden of U.S. patients with bone metastases is significant and was estimated to be $ 12.6 billion last year .", "label": "", "metadata": {}, "score": "59.682556"}
{"text": "Discussion .Prostate cancer is the most frequently diagnosed cancer and is second only to lung cancer as the leading cause of cancer - related deaths among in the USA .", "label": "", "metadata": {}, "score": "59.762405"}
{"text": "The Radiation Therapy Oncology Group ( RTOG ) has previously studied various treatment fraction regimens for palliation of bone metastases .However , this study evaluation point for pain relief is very early , at 3 months after radiotherapy .", "label": "", "metadata": {}, "score": "60.09278"}
{"text": "They have shown that the number of metastatic lesions is a powerful prognostic indicator of the outcome in metastatic disease .On the basis of this result , we grouped our prostate cancer patients with bone metastases likewise and applied radiotherapy to metastatic bone disease in EOD I cases ( i.e. , oligometastases and oligo - recurrence of bone in prostate cancer ) regardless of the presence of the bone pain .", "label": "", "metadata": {}, "score": "60.129944"}
{"text": "Radiotherapy of bone oligometastases in PCa was effective for long - term pain relief .Pathological fracture and SCC were not seen at the treated sites .", "label": "", "metadata": {}, "score": "60.16854"}
{"text": "This study also demonstrated that the 2-year survival rate in prostate cancer patients with EOD I , defined as having fewer than six bone metastases on bone scan , was 94 % .", "label": "", "metadata": {}, "score": "60.70226"}
{"text": "Table 1 shows the baseline characteristics of the study population according to the total radiotherapy dose .In prior treatment to the primary site , radical prostatectomy was performed in 10 patients , and radiotherapy including conformal external beam radiotherapy ( 3DCRT ) alone and high dose rate brachytherapy ( HDR ) in combination with 3DCRT ( HDR/3DCRT ) was performed in eight patients .", "label": "", "metadata": {}, "score": "60.789825"}
{"text": "The current study demonstrated that the complications were not seen in treated sites ; however , three patients experienced pathological fracture and one patient had spinal cord compression in a nontreated site after radiotherapy .", "label": "", "metadata": {}, "score": "60.819263"}
{"text": "Many studies have been performed along these lines [ 6 - 10 ] .Niibe et al .[ 8 ] also indicated that high - dose radiotherapy for bone metastases could contribute to patient survival in breast cancer .", "label": "", "metadata": {}, "score": "60.859367"}
{"text": "All are serious complications for advanced cancer patients .The economic burden of United States ( U.S. ) patients with bone metastases is significant and was estimated to be $ 12.6 billion last year .", "label": "", "metadata": {}, "score": "60.88304"}
{"text": "All are serious complications for advanced cancer patients .The economic burden of United States ( U.S. ) patients with bone metastases is significant and was estimated to be $ 12.6 billion last year .", "label": "", "metadata": {}, "score": "60.88304"}
{"text": "Pathological fracture and spinal cord compression ( SCC ) were not seen at the treated sites but developed at nonirradiated sites in three patients ( 8.6 % ) and in one patient ( 2.8 % ) , respectively .", "label": "", "metadata": {}, "score": "61.122948"}
{"text": "Counting began from randomization in the way that every counted event was followed by a 20-day period during which no SRE was counted , nor was the time counted as \" at risk \" .", "label": "", "metadata": {}, "score": "61.25986"}
{"text": "An estimated 30 % to 40 % of patients with NSCLC develop bone metastases , which is associated with osteoclast - driven bone destruction .The bone disease predisposes patients to skeletal - related events ( SREs ) that include pathologic fracture , radiation or surgery to bone , spinal cord compression , and hypercalcemia of malignancy .", "label": "", "metadata": {}, "score": "61.834087"}
{"text": "There was no statistically significant difference in the rate of ONJ between the two treatment arms .Infectious adverse events were balanced between the two treatment arms , as was overall survival and the time to cancer progression .", "label": "", "metadata": {}, "score": "62.50084"}
{"text": "Figure 3 shows the progression - free survival for bone pain .One - year progression - free survival was 64.8 % , and the median duration of pain relief was 12 months ( range , 5 - 68 months ) .", "label": "", "metadata": {}, "score": "62.864395"}
{"text": "Abstract .Purpose .To retrospectively evaluate the clinical significance of radiotherapy for oligometastases of bone in prostate cancer ( PCa ) .Methods and Materials .", "label": "", "metadata": {}, "score": "63.249607"}
{"text": "Bone Metastases : Prevalence and Impact .Bone metastases occur in more than 1.5 million patients with cancer worldwide and are most commonly associated with cancers of the prostate , lung , and breast , with incidence rates as high as 75 percent of patients with metastatic disease .", "label": "", "metadata": {}, "score": "63.5497"}
{"text": "Diagnosis of metabolic bone disease other than osteoporosis ( e.g. , Paget 's disease of bone ) .Known hypersensitivity to Zometa .Treatment with other investigational drugs within 30 days prior to randomization .", "label": "", "metadata": {}, "score": "63.76101"}
{"text": "Niibe et al .[ 8 ] and Niibe and Hayakawa [ 9 ] also proposed oligo - recurrence , a more strictly defined type of oligometastases , in which one or several metastatic or recurrent lesions occur with the controlled primary lesions .", "label": "", "metadata": {}, "score": "63.764767"}
{"text": "The economic burden of U.S. patients with bone metastases is significant and is estimated to be $ 12.6 billion annually[ii].Patients with bone metastases who experience an SRE incur significantly higher medical costs compared with those who do not experience an SRE [ iii].", "label": "", "metadata": {}, "score": "64.17799"}
{"text": "Such events can profoundly disrupt a patient 's life and can cause disability , pain or even death .( vi ) ( vii ) ( viii ) .", "label": "", "metadata": {}, "score": "64.57743"}
{"text": "Oligo - recurrence is the state that cancer patients with one to several metastases or recurrences have controlled primary lesions .Niibe and Hayakawa proposed this notion as oligo - recurrence [ 9 ] .", "label": "", "metadata": {}, "score": "65.050186"}
{"text": "( v )Such events can profoundly disrupt a patient 's life and can cause disability , pain or even death .( vi ) ( vii ) ( viii ) .", "label": "", "metadata": {}, "score": "65.19323"}
{"text": "Radiotherapy was performed using one port postero - anterior field for the middle thoracic spine / upper lumbar spine and two ports anteroposterior parallel opposed fields for the other spine , legs , and pelvic bone .", "label": "", "metadata": {}, "score": "66.12532"}
{"text": "All patients were strongly recommended to take daily calcium and vitamin D supplements .The primary endpoint was time to first on - study SRE .", "label": "", "metadata": {}, "score": "66.939865"}
{"text": "This damage can result in a number of serious bone complications , collectively called SREs .This was an international Phase 3 , randomized , double - blind study comparing denosumab with Zometa in the treatment of bone metastases in patients with advanced breast cancer .", "label": "", "metadata": {}, "score": "67.16737"}
{"text": "Change From Baseline in Mean Composite Brief Pain Inventory ( BPI )Score [ Time Frame : baseline , 52 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "67.84722"}
{"text": "The authors declare that they have no conflict of Interests .References . A. Berruti , L. Dogliotti , R. Bitossi et al . , \" Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease : predictive role of bone resorption and formation markers evaluated at baseline , \" Journal of Urology , vol .", "label": "", "metadata": {}, "score": "68.33751"}
{"text": "We look forward to reviewing the results from a second Phase 3 study of denosumab effects in advanced cancer patients later this year . \" Bone metastases , the spread of tumors to the bone , are a serious concern for advanced breast cancer patients , with incidence rates as high as 75 percent .", "label": "", "metadata": {}, "score": "69.13179"}
{"text": "Skeletal Morbidity Rate [ Time Frame : 52 weeks ] [ Designated as safety issue : No ] .An SMR for a patient was defined as the \" number of occurrences \" of any ( or a particular ) SRE allowing for only 1 event in any 3-week interval , divided by the \" time at risk \" in years .", "label": "", "metadata": {}, "score": "69.36563"}
{"text": "Anti - resorptive agents , such as bisphosphonates , have been the mainstay of treatment for cancer - induced bone disease .Among available agents , zoledronic acid has been shown to reduce SREs in patents with solid tumors , including lung cancer .", "label": "", "metadata": {}, "score": "69.45123"}
{"text": "View at Google Scholar .J. L. Lopez Guerra , D. Gomez , Y. Zhuang , et al . , \" Prognostic impact of radiation therapy to the primary tumor in patients with non - small cell lung cancer and oligometastasis at diagnosis , \" International Journal of Radiation Oncology , vol .", "label": "", "metadata": {}, "score": "69.65289"}
{"text": "Bone metastases occur in more than 1.5 million patients with cancer worldwide and are most commonly associated with cancers of the prostate , lung , and breast , with incidence rates as high as 75 percent of patients with metastatic disease .", "label": "", "metadata": {}, "score": "69.657745"}
{"text": "This international , head - to - head , randomized , double - blind study enrolled 1,901 men with bone metastases from hormone - refractory prostate cancer .", "label": "", "metadata": {}, "score": "69.6767"}
{"text": "Figure 1 shows the overall survival curves after radiotherapy for metastatic bone disease .The 3-year overall survival rate for all patients was 77.2 % .", "label": "", "metadata": {}, "score": "69.95836"}
{"text": "( ix ) Delea T , Langer C , McKiernan J , et al .The cost of treatment of skeletal - related events in patients with bone metastases from lung cancer .", "label": "", "metadata": {}, "score": "70.37337"}
{"text": "( ix ) Delea T , Langer C , McKiernan J , et al .The cost of treatment of skeletal - related events in patients with bone metastases from lung cancer .", "label": "", "metadata": {}, "score": "70.37337"}
{"text": "( ix ) ( x ) ( xi ) Studies have shown that the costs of treating a SRE are significant .( x ) ( xii )", "label": "", "metadata": {}, "score": "70.402725"}
{"text": "( ix ) ( x ) ( xi ) Studies have shown that the costs of treating a SRE are significant .( x ) ( xii )", "label": "", "metadata": {}, "score": "70.402725"}
{"text": "Therefore all potential confounding factors of radiotherapy dose were reduced to one single composite characteristic by applying a propensity score [ 13 ] .The conventional .", "label": "", "metadata": {}, "score": "70.40861"}
{"text": "12 , pp .899 - 911 , 2001 .View at Google Scholar \u00b7 View at Scopus .M. S. Soloway , S. W. Hardeman , D. Hickey et al . , \" Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan , \" Cancer , vol .", "label": "", "metadata": {}, "score": "70.778946"}
{"text": "The bone pain trial which include 34 % of prostate cancer patients in patient population showed 40 % of pain relapse at 12 months [ 18 ] .", "label": "", "metadata": {}, "score": "70.79274"}
{"text": "Niibe et al . reported high - dose radiation contributed to long - term pain relief in breast cancer [ 8 ] .Milano et al . also reported high - dose stereotactic body radiotherapy for bone oligometastases , oligo - recurrence was efficacious [ 19 ] .", "label": "", "metadata": {}, "score": "70.85193"}
{"text": "\" This observation may point toward potential effects of denosumab beyond the skeleton . \"\" The strength of these data lies in the large number of patients evaluated and the consistency of the observation across subsets , whereas the limitation of these data is the retrospective nature of the analysis , \" they added .", "label": "", "metadata": {}, "score": "70.85663"}
{"text": "The survival rate was calculated using the Kaplan - Meier method .Differences in patient characteristics between the two groups were compared by chi - square test or Fisher exact test , as appropriate .", "label": "", "metadata": {}, "score": "70.90135"}
{"text": "Poster .( xii ) Lage MJ , Barber BL , Harrison DJ , Jun S. The Cost of Treating Skeletal - Related Events in Patients With Prostate Cancer .", "label": "", "metadata": {}, "score": "71.003494"}
{"text": "Poster .( xii ) Lage MJ , Barber BL , Harrison DJ , Jun S. The Cost of Treating Skeletal - Related Events in Patients With Prostate Cancer .", "label": "", "metadata": {}, "score": "71.003494"}
{"text": "The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future .", "label": "", "metadata": {}, "score": "71.03205"}
{"text": "The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future .", "label": "", "metadata": {}, "score": "71.03205"}
{"text": "Further , preclinical results do not guarantee safe and effective performance of product candidates in humans .The complexity of the human body can not be perfectly , or sometimes , even adequately modeled by computer or cell culture systems or animal models .", "label": "", "metadata": {}, "score": "71.18035"}
{"text": "Further , preclinical results do not guarantee safe and effective performance of product candidates in humans .The complexity of the human body can not be perfectly , or sometimes , even adequately modeled by computer or cell culture systems or animal models .", "label": "", "metadata": {}, "score": "71.18035"}
{"text": "Further , preclinical results do not guarantee safe and effective performance of product candidates in humans .The complexity of the human body can not be perfectly , or sometimes , even adequately modeled by computer or cell culture systems or animal models .", "label": "", "metadata": {}, "score": "71.18035"}
{"text": "Further , preclinical results do not guarantee safe and effective performance of product candidates in humans .The complexity of the human body can not be perfectly , or sometimes , even adequately modeled by computer or cell culture systems or animal models .", "label": "", "metadata": {}, "score": "71.18035"}
{"text": "The median time to first on - study SRE was not reached for denosumab and therefore could not be estimated .The median time to first on - study SRE was 26.5 months for Zometa , the current standard of care .", "label": "", "metadata": {}, "score": "71.21741"}
{"text": "These three studies form the basis of the clinical evidence package for denosumab in advanced cancer , and were submitted to regulatory authorities in the United States ( U.S. ) and in the European Union ( EU ) .", "label": "", "metadata": {}, "score": "71.27282"}
{"text": "A positive change from baseline indicates worsening .Change From Baseline in Mean Analgesic Score [ Time Frame : baseline , 52 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "71.302734"}
{"text": "The most favorable prognostic factor of oligometastases is the state of primary lesion , which means that oligometastatic patients with controlled primary lesions achieve significant better survival than those with active primary lesions [ 11 , 12 ] .", "label": "", "metadata": {}, "score": "71.46023"}
{"text": "Textbook of Bone Metastases .Hoboken , NJ : Edition : John Wiley and Sons ; 2005:105 .( 4 ) Mundy GR .Metastasis to bone : causes , consequences and therapeutic opportunities .", "label": "", "metadata": {}, "score": "72.08096"}
{"text": "Textbook of Bone Metastases .Hoboken , NJ : Edition : John Wiley and Sons ; 2005:105 .( 4 ) Mundy GR .Metastasis to bone : causes , consequences and therapeutic opportunities .", "label": "", "metadata": {}, "score": "72.08096"}
{"text": "Change From Baseline in Serum Bone Specific Alkaline Phosphatase [ Time Frame : baseline , 48 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "72.56584"}
{"text": "The primary endpoint was to evaluate if denosumab is non - inferior to Zometa with respect to the first on - study SRE in patients with advanced prostate cancer and bone metastases .", "label": "", "metadata": {}, "score": "72.85788"}
{"text": "21 , pp .3388 - 3393 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Bayley , M. Milosevic , R. Blend et al . , \" A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma , \" Cancer , vol .", "label": "", "metadata": {}, "score": "72.87099"}
{"text": "4 , pp .1248 - 1253 , 2000 .View at Google Scholar \u00b7 View at Scopus .R. C. M. Pelger , V. Soerdjbalie - Maikoe , and N. A. T. Hamdy , \" Strategies for management of prostate cancer - related bone pain , \" Drugs and Aging , vol .", "label": "", "metadata": {}, "score": "73.089264"}
{"text": "Both results were statistically significant in this 34 month study .The median time to first on - study SRE was not reached for denosumab and therefore could not be estimated .", "label": "", "metadata": {}, "score": "73.13098"}
{"text": "Results .The median radiotherapy dose was 40 Gy . , were 77.2 % , 90.5 % , and 50.0 % , respectively .Fourteen out of 16 patients ( 87.5 % ) who had pain were improved 1 month after radiotherapy .", "label": "", "metadata": {}, "score": "73.408844"}
{"text": "The treatment outcomes are shown in Table 3 .At 1 month after radiotherapy , 14 out of 16 patients ( 87.5 % ) with pain gained relief .", "label": "", "metadata": {}, "score": "73.63527"}
{"text": "Median survival improved from 7.7 months with zoledronic acid to 8.9 months with denosumab .A subgroup analysis showed that the overall benefit was driven by improved survival in patients with non - small cell lung cancer ( NSCLC ) , according to Giorgio V. Scagliotti , MD , of the University of Turino in Orbassano , Italy .", "label": "", "metadata": {}, "score": "73.71178"}
{"text": "[ 3 ] as the presence of fewer than six bone metastases on bone scan , with each site being less than 50 % the size of a vertebral body .", "label": "", "metadata": {}, "score": "74.098145"}
{"text": "No forward - looking statement can be guaranteed and actual results may differ materially from those we project .Further , preclinical results do not guarantee safe and effective performance of product candidates in humans .", "label": "", "metadata": {}, "score": "74.778694"}
{"text": "No forward - looking statement can be guaranteed and actual results may differ materially from those we project .Further , preclinical results do not guarantee safe and effective performance of product candidates in humans .", "label": "", "metadata": {}, "score": "74.778694"}
{"text": "Thirty - five of the patients had bone metastases of EOD I , referred to as oligometastases or oligo - recurrence of bone in this study .", "label": "", "metadata": {}, "score": "74.837265"}
{"text": "The median biologically effective dose ( BED ) was 67 Gy 3 ( range , 50 - 92 Gy 3 ) if \u03b1 / \u03b2 of 3 was applied .", "label": "", "metadata": {}, "score": "75.08353"}
{"text": "July 2013 ( final data collection date for primary outcome measure ) .Eligibility Criteria ICMJE .Inclusion Criteria : .Confirmed breast cancer with bone metastasis .", "label": "", "metadata": {}, "score": "75.40228"}
{"text": "Treatment was well tolerated .July 13 , 2009 .Amgen released positive results from a phase III trial of denosumab for the treatment of bone metastases due to breast cancer .", "label": "", "metadata": {}, "score": "75.45009"}
{"text": "Exclusion Criteria : .Abnormal kidney function determined by serum creatinine levels .Current active dental problems including : ongoing infection of the teeth or jawbone ; current exposed bone in the mouth ; and current or prior diagnosis of osteonecrosis of the jaw .", "label": "", "metadata": {}, "score": "75.52197"}
{"text": "67 , no . 3 , pp .375 - 382 , 1985 .View at Google Scholar \u00b7 View at Scopus . D. Rades , F. Fehlauer , R. Schulte et al . , \" Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "75.6469"}
{"text": "11 , pp .798 - 804 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . K. P. Weinfurt , Y. Li , L. D. Castel et al . , \" The significance of skeletal - related events for the health - related quality of life of patients with metastatic prostate cancer , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "75.71203"}
{"text": "( x ) Schulman KL , Kohles J. Economic burden of metastic bone disease in the U.S. American Cancer Society 2007:2334 - 2342 .( xi ) GVD/2007:2334 - 2342 .", "label": "", "metadata": {}, "score": "75.7174"}
{"text": "( x ) Schulman KL , Kohles J. Economic burden of metastic bone disease in the U.S. American Cancer Society 2007:2334 - 2342 .( xi ) GVD/2007:2334 - 2342 .", "label": "", "metadata": {}, "score": "75.7174"}
{"text": "Our products may compete against products that have lower prices , established reimbursement , superior performance , are easier to administer , or that are otherwise competitive with our products .", "label": "", "metadata": {}, "score": "75.71817"}
{"text": "Our products may compete against products that have lower prices , established reimbursement , superior performance , are easier to administer , or that are otherwise competitive with our products .", "label": "", "metadata": {}, "score": "75.71817"}
{"text": "Our products may compete against products that have lower prices , established reimbursement , superior performance , are easier to administer , or that are otherwise competitive with our products .", "label": "", "metadata": {}, "score": "75.71817"}
{"text": "Our products may compete against products that have lower prices , established reimbursement , superior performance , are easier to administer , or that are otherwise competitive with our products .", "label": "", "metadata": {}, "score": "75.71817"}
{"text": "Our products may compete against products that have lower prices , established reimbursement , superior performance , are easier to administer , or that are otherwise competitive with our products .", "label": "", "metadata": {}, "score": "75.71817"}
{"text": "Our products may compete against products that have lower prices , established reimbursement , superior performance , are easier to administer , or that are otherwise competitive with our products .", "label": "", "metadata": {}, "score": "75.71817"}
{"text": "effective palliative treatment in women with breast carcinoma and osteolytic bone metastases .Cancer 2000;88:1082 - 1090 .( iii )Saad F , Lipton A , Cook R , Chen YM , Smith M , Coleman R. Pathologic fractures correlated with reduced survival in patients with malignant bone disease .", "label": "", "metadata": {}, "score": "75.762184"}
{"text": "The primary endpoint was to evaluate if denosumab is non - inferior to Zometa with respect to the first , on - study SRE in patients with advanced breast cancer and bone metastases .", "label": "", "metadata": {}, "score": "75.801636"}
{"text": "The primary endpoint was to evaluate if denosumab is non - inferior to Zometa with respect to the first , on - study SRE in patients with advanced breast cancer and bone metastases .", "label": "", "metadata": {}, "score": "75.801636"}
{"text": "Bone Metastases .October 3 , 2011 .Bayer Healthcare issued results from a phase III trial of radium-223 chloride for castration - resistant prostate cancer and symptomatic bone metastases .", "label": "", "metadata": {}, "score": "76.2292"}
{"text": "\" The median time to first on - study SRE or HCM was not reached for denosumab and therefore could not be estimated .The median time to first on - study SRE or HCM was 25.2 months for Zometa .", "label": "", "metadata": {}, "score": "76.23671"}
{"text": "\" The median time to first on - study SRE or HCM was not reached for denosumab and therefore could not be estimated .The median time to first on - study SRE or HCM was 25.2 months for Zometa .", "label": "", "metadata": {}, "score": "76.23671"}
{"text": "( Date:2/8/2016 ) ... , Feb. 8 , 2016 Should antibiotic ... bone cement products to prevent infection after standard total ... the experts at ECRI Institute have been fielding a ... or Fighting Your Bottom Line ?", "label": "", "metadata": {}, "score": "76.50145"}
{"text": "( vii )Johnell O , Kanis JA .An estimate of the worldwide prevalence and disability associated with osteoporotic fractures .Osteoporos Int 2006;17:1726 - 1733 .", "label": "", "metadata": {}, "score": "76.66138"}
{"text": "( vii )Johnell O , Kanis JA .An estimate of the worldwide prevalence and disability associated with osteoporotic fractures .Osteoporos Int 2006;17:17261733 .", "label": "", "metadata": {}, "score": "76.76139"}
{"text": "The primary endpoint was to determine if denosumab is non - inferior to Zometa with respect to the first on - study skeletal - related event ( SRE 's ) .", "label": "", "metadata": {}, "score": "77.35852"}
{"text": "Gender .Female .Ages .18 Years and older .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects The study met its primary and secondary endpoints and demonstrated denosumab 's superiority over Zometa in delaying or preventing skeletal related events ( SREs ) .", "label": "", "metadata": {}, "score": "77.50686"}
{"text": "788 - 794 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y.Niibe , T. Nishimura , T. Inoue , et al . , \" Oligometastases of brain only in patients with non - small cell lung cancer ( NSCLC ) treated with stereotactic irradiation ( STI ) : a multi - institutional study , \" International Journal of Radiation Oncology , vol .", "label": "", "metadata": {}, "score": "77.641594"}
{"text": "The primary endpoint was to evaluate if denosumab is non - inferior to Zometa with respect to the first on - study SRE in patients with advanced breast cancer and bone metastases .", "label": "", "metadata": {}, "score": "77.955154"}
{"text": "2Coleman RE .Metastatic bone disease : clinical features , pathophysiology and treatment strategies .Cancer Treat Rev. 2001;27:165 - 76 .( 3 ) Capanna R , Coia LR , Coleman R. et al .", "label": "", "metadata": {}, "score": "78.062935"}
{"text": "2Coleman RE .Metastatic bone disease : clinical features , pathophysiology and treatment strategies .Cancer Treat Rev. 2001;27:165 - 76 .( 3 ) Capanna R , Coia LR , Coleman R. et al .", "label": "", "metadata": {}, "score": "78.062935"}
{"text": "( xiii ) Schulman KL , Kohles J. Economic burden of metastic bone disease in the U.S. American Cancer Society 2007:2334 - 2342 .( Date:2/11/2016 ) ... -- Breast Cancer Therapeutics in Asia - Pacific Markets to ...", "label": "", "metadata": {}, "score": "78.3244"}
{"text": "Saad F , Gleason DM , Murray R , et al .A Randomized , Placebo - Controlled Trial of Zoledronic Acid in Patients With Hormone - Refractory Metastatic Prostate Carcinoma .", "label": "", "metadata": {}, "score": "78.4673"}
{"text": "Saad F , Gleason DM , Murray R , et al .A Randomized , Placebo - Controlled Trial of Zoledronic Acid in Patients With Hormone - Refractory Metastatic Prostate Carcinoma .", "label": "", "metadata": {}, "score": "78.4673"}
{"text": "Overall survival and the time to cancer progression were similar between the treatment arms .October 21 , 2002 .Novartis reported positive results from a study to examine the long - term efficacy of Zometa .", "label": "", "metadata": {}, "score": "78.64395"}
{"text": "12 , pp .1587 - 1593 , 2004 .View at Google Scholar \u00b7 View at Scopus .P. Sabbatini , S. M. Larson , A. Kremer et al . , \" Prognostic significance of extent of disease in bone in patients with androgen - independent prostate cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "78.8655"}
{"text": "( iv ) Rosen LS , Gordon D , Tchekmedyian NS , et al .Nonsmall cell lung carcinoma and other solid tumors .Cancer .", "label": "", "metadata": {}, "score": "78.90541"}
{"text": "( iv ) Rosen LS , Gordon D , Tchekmedyian NS , et al .Nonsmall cell lung carcinoma and other solid tumors .Cancer .", "label": "", "metadata": {}, "score": "78.90541"}
{"text": "( xiii ) Schulman KL , Kohles J. Economic burden of metastic bone disease in the U.S. American Cancer Society 2007:2334 - 2342 .These results were presented today during the Presidential Session at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin , Germany ( Abstract Number 2LBA ) .", "label": "", "metadata": {}, "score": "78.93822"}
{"text": "\" Patients with bone metastases from cancer are at increased risk of experiencing debilitating pathologic fractures and other skeletal - related events . \"In addition to improving skeletal outcomes , denosumab has no requirement for renal monitoring and is administered as a simple subcutaneous injection . \"", "label": "", "metadata": {}, "score": "79.193436"}
{"text": "Our business may be impacted by government investigations , litigation and products liability claims .We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development .", "label": "", "metadata": {}, "score": "79.22928"}
{"text": "Our business may be impacted by government investigations , litigation and products liability claims .We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development .", "label": "", "metadata": {}, "score": "79.22928"}
{"text": "Our business may be impacted by government investigations , litigation and products liability claims .We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development .", "label": "", "metadata": {}, "score": "79.22928"}
{"text": "Our business may be impacted by government investigations , litigation and products liability claims .We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development .", "label": "", "metadata": {}, "score": "79.22928"}
{"text": "Our business may be impacted by government investigations , litigation and products liability claims .We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development .", "label": "", "metadata": {}, "score": "79.22928"}
{"text": "Our business may be impacted by government investigations , litigation and products liability claims .We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development .", "label": "", "metadata": {}, "score": "79.22928"}
{"text": "948 - 957 , 1999 .View at Google Scholar \u00b7 View at Scopus . A. Rana , G. D. Chisholm , M. Khan , S. S. Sekharjit , M. V. Merrick , and R. A. Elton , \" Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate , \" British Journal of Urology , vol .", "label": "", "metadata": {}, "score": "79.74987"}
{"text": "A positive change from baseline indicates worsening .Change From Baseline in Urinary N - telopeptide / Creatinine Ratio [ Time Frame : baseline , 48 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "79.78714"}
{"text": "On the other hand , there were three patients ( 8.6 % ) with pathological fracture and one patient ( 2.8 % ) with spinal cord compression in nontreated sites after radiotherapy .", "label": "", "metadata": {}, "score": "80.02472"}
{"text": "61 - 67 , 2012 .View at Google Scholar .M. S. Cepeda , R. Boston , J. T. Farrar , and B. L. Strom , \" Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders , \" American Journal of Epidemiology , vol .", "label": "", "metadata": {}, "score": "80.048485"}
{"text": "Official Title ICMJE .A Prospective , Randomized , Double - blind , Stratified , Multi - center , 2-arm Trial of the Continued Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks ) in in the 2nd Year of Treatment in Patients With Documented Bone Metastases From Breast Cancer .", "label": "", "metadata": {}, "score": "80.26217"}
{"text": "195 - 202 , 1988 .View at Google Scholar \u00b7 View at Scopus . S. Koswig and V. Budach , \" Recalcification and pain relief following radiotherapy for bone metastases .", "label": "", "metadata": {}, "score": "80.49183"}
{"text": "Approved for prevention of SREs in patients with solid tumors and bone metastases , denosumab demonstrated noninferiority to zoledronic acid for delaying time to first SRE in a phase III randomized trial .", "label": "", "metadata": {}, "score": "80.69644"}
{"text": "Cancer .1997 ; 80(suppl ) : 1588 - 1594 .( ii ) Lipton A , Theriault RL , Hortobagyi GN .Pamidronate prevents skeletal complications and is .", "label": "", "metadata": {}, "score": "80.9849"}
{"text": "A Cox proportional hazards model was applied to estimate the effect of radiotherapy dose on overall survival . , which indicated that high - dose group decreased the hazard of death by four times that of low - dose group ( Table 4 ) .", "label": "", "metadata": {}, "score": "81.003265"}
{"text": "Clinical trial in breast cancer patients with bone metastases pretreated for approximately 1 year with a standard zoledronic acid regimen .Looking at the continued effectiveness and safety of giving zoledronic acid every 4 weeks versus every 12 weeks given over 1 year .", "label": "", "metadata": {}, "score": "81.28584"}
{"text": "Amgen issued positive results from a phase III trial of denosumab for the treatment of bone metastases due to solid tumors or multiple myeloma .This international , randomized , double - blind , active controlled study enrolled 1,776 subjects with advanced cancer .", "label": "", "metadata": {}, "score": "81.286545"}
{"text": "5 , pp .1516 - 1522 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W. F. Harstell , C. B. Scott , D. W. Bruner et al . , \" Randomized trial of short- versus long - course radiotherapy for palliation of painful bone metastases , \" Journal of the National Cancer Institute , vol .", "label": "", "metadata": {}, "score": "81.3564"}
{"text": "A biotechnology pioneer since 1980 , Amgen was one of the first companies to realize the new science 's promise by bringing safe and effective medicines from lab , to manufacturing plant , to patient .", "label": "", "metadata": {}, "score": "81.531"}
{"text": "We were also interested in the disease behavior in patients with bone oligometastases and oligo - recurrence .Methods and Materials .Between January 2003 and December 2008 , 136 Japanese men diagnosed with prostate cancer with bone metastases received radiotherapy directed at the metastatic bone lesions at Kitasato University Hospital , Japan .", "label": "", "metadata": {}, "score": "81.63804"}
{"text": "This study was an international , Phase 3 , randomized , double - blind study comparing denosumab with Zometa in the treatment of bone metastases in patients with advanced prostate cancer .", "label": "", "metadata": {}, "score": "81.66667"}
{"text": "Analysis of the NSCLC results by tumor histology showed more than a 2-month difference in survival in patients with squamous - cell cancer randomized to denosumab , they reported online in the Journal of Thoracic Oncology .", "label": "", "metadata": {}, "score": "81.789566"}
{"text": "280 - 287 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. B. Wyatt , R. F. S\u00e1nchez - Ortiz , C. G. Wood , E. Ramirez , C. Logothetis , and C. A. Pettaway , \" Prognostic factors for survival among Caucasian , African - American and Hispanic men with androgen - independent prostate cancer , \" Journal of the National Medical Association , vol .", "label": "", "metadata": {}, "score": "81.81593"}
{"text": "Scagliotti and colleagues reported findings from a post hoc subgroup analysis of the phase III trial , limited to patients with lung cancer .The trial included 811 patients with lung cancer , including 702 patients with NSCLC and 109 with small - cell lung cancer ( SCLC ) .", "label": "", "metadata": {}, "score": "81.84589"}
{"text": "( i ) Coleman RE .Skeletal complications of malignancy .Cancer .1997 ; 80(suppl ) : 1588 - 1594 .( ii ) Lipton A , Theriault RL , Hortobagyi GN .", "label": "", "metadata": {}, "score": "82.496475"}
{"text": "Amgen discovers , develops and delivers innovative human therapeutics .A biotechnology pioneer since 1980 , Amgen was one of the first companies to realize the new science 's promise by bringing safe and effective medicines from lab , to manufacturing plant , to patient .", "label": "", "metadata": {}, "score": "83.34302"}
{"text": "Amgen discovers , develops and delivers innovative human therapeutics .A biotechnology pioneer since 1980 , Amgen was one of the first companies to realize the new science 's promise by bringing safe and effective medicines from lab , to manufacturing plant , to patient .", "label": "", "metadata": {}, "score": "83.34302"}
{"text": "Amgen discovers , develops and delivers innovative human therapeutics .A biotechnology pioneer since 1980 , Amgen was one of the first companies to realize the new science 's promise by bringing safe and effective medicines from lab , to manufacturing plant , to patient .", "label": "", "metadata": {}, "score": "83.34302"}
{"text": "4 , pp .579 - 584 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Siegal and T. Siegal , \" Vertebral body resection for epidural compression by malignant tumors .", "label": "", "metadata": {}, "score": "83.40077"}
{"text": "28 , no .6 , pp .3929 - 3931 , 2008 .View at Google Scholar \u00b7 View at Scopus .T. Inoue , N. Katoh , H. Aoyama et al . , \" Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions , \" Japanese Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "83.55768"}
{"text": "In Japan , longer courses of radiotherapy with higher total doses of radiation remain the most commonly used , typically with a regimen of 30 - 40 Gy given in 10 - 20 treatment sessions .", "label": "", "metadata": {}, "score": "84.24713"}
{"text": "Drug : Zoledronic acid .Drug : Placebo .Experimental : Placebo / zoledronic acid .Participants randomized to this arm received placebo but the arm was later dropped and participants in this arm were swithced to the zoledronic acid q 4 weeks according to a study amendment .", "label": "", "metadata": {}, "score": "84.29916"}
{"text": "\" Denosumab was superior to Zometa in preventing skeletal related events and delayed worsening of bone pain .In addition , denosumab also presented some potential tolerability advantages for many patients , including a lower incidence of renal toxicity and acute phase reactions , combined with the convenience of a monthly subcutaneous injection .", "label": "", "metadata": {}, "score": "84.68935"}
{"text": "6 , pp .933 - 936 , 1993 .View at Google Scholar \u00b7 View at Scopus .J. R. Yarnold , \" 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain : randomised comparison with a multifraction schedule over 12 months of patient follow - up , \" Radiotherapy and Oncology , vol .", "label": "", "metadata": {}, "score": "84.86753"}
{"text": "In addition , denosumab also presented some potential tolerability advantages for many patients , including a lower incidence of renal toxicity and acute phase reactions , combined with the convenience of a monthly subcutaneous injection .", "label": "", "metadata": {}, "score": "84.94414"}
{"text": "Amgen discovers , develops , manufactures and delivers innovative human therapeutics .A biotechnology pioneer since 1980 , Amgen was one of the first companies to realize the new science 's promise by bringing safe and effective medicines from lab , to manufacturing plant , to patient .", "label": "", "metadata": {}, "score": "84.96736"}
{"text": "Amgen discovers , develops , manufactures and delivers innovative human therapeutics .A biotechnology pioneer since 1980 , Amgen was one of the first companies to realize the new science 's promise by bringing safe and effective medicines from lab , to manufacturing plant , to patient .", "label": "", "metadata": {}, "score": "84.96736"}
{"text": "Cancer 2000;88:1082 - 1090 .( iii )Saad F , Lipton A , Cook R , Chen YM , Smith M , Coleman R. Pathologic fractures correlated with reduced survival in patients with malignant bone disease .", "label": "", "metadata": {}, "score": "85.02897"}
{"text": "Only the FDA can determine whether the products are safe and effective for these uses .Healthcare professionals should refer to and rely upon the FDA - approved labeling for the products , and not the information discussed in this news release .", "label": "", "metadata": {}, "score": "85.31318"}
{"text": "Only the FDA can determine whether the products are safe and effective for these uses .Healthcare professionals should refer to and rely upon the FDA - approved labeling for the products , and not the information discussed in this news release .", "label": "", "metadata": {}, "score": "85.31318"}
{"text": "Only the FDA can determine whether the products are safe and effective for these uses .Healthcare professionals should refer to and rely upon the FDA - approved labeling for the products , and not the information discussed in this news release .", "label": "", "metadata": {}, "score": "85.31318"}
{"text": "Only the FDA can determine whether the products are safe and effective for these uses .Healthcare professionals should refer to and rely upon the FDA - approved labeling for the products , and not the information discussed in this news release .", "label": "", "metadata": {}, "score": "85.31318"}
{"text": "Only the FDA can determine whether the products are safe and effective for these uses .Healthcare professionals should refer to and rely upon the FDA - approved labeling for the products , and not the information discussed in this news release .", "label": "", "metadata": {}, "score": "85.31318"}
{"text": "Only the FDA can determine whether the products are safe and effective for these uses .Healthcare professionals should refer to and rely upon the FDA - approved labeling for the products , and not the information discussed in this news release .", "label": "", "metadata": {}, "score": "85.31318"}
{"text": "The subjects received Alpharadin plus best standard of care or placebo plus best standard of care .The primary endpoint was overall survival .February 15 , 2010 .", "label": "", "metadata": {}, "score": "86.180885"}
{"text": "Other seventeen patients are called as oligometastases group in this study .All 35 patients received hormonal therapy .Nine patients received Zoledronic acid .Treatment characteristics are given in Table 2 .", "label": "", "metadata": {}, "score": "86.2307"}
{"text": "Not Provided .Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .", "label": "", "metadata": {}, "score": "86.29942"}
{"text": "This was an international , Phase 3 , randomized , double - blind study comparing denosumab with Zometa in the treatment of bone metastases in patients with advanced breast cancer .", "label": "", "metadata": {}, "score": "87.107086"}
{"text": "This was an international , Phase 3 , randomized , double - blind study comparing denosumab with Zometa in the treatment of bone metastases in patients with advanced breast cancer .", "label": "", "metadata": {}, "score": "87.107086"}
{"text": "Detailed data from another Phase 3 , head - to - head trial evaluating denosumab versus Zometa was presented yesterday ( Abstract # 20LBA ) .", "label": "", "metadata": {}, "score": "87.285034"}
{"text": "Detailed data from another Phase 3 , head - to - head trial evaluating denosumab versus Zometa was presented yesterday ( Abstract # 20LBA ) .", "label": "", "metadata": {}, "score": "87.285034"}
{"text": "Among patients with adenocarcinoma , median survival was 9.6 months with denosumab and 8.2 months with zoledronic acid , a difference that did not achieve statistical significance .", "label": "", "metadata": {}, "score": "87.37008"}
{"text": "The study , published today in the Journal of Clinical Oncology , found that denosumab was superior to Zometa in delaying or preventing SREs in breast cancer patients with bone metastases .", "label": "", "metadata": {}, "score": "87.43181"}
{"text": "Drug : Zoledronic acid .Drug : Placebo .Not Provided .Recruitment Status ICMJE .Completed .Enrollment ICMJE .Completion Date .July 2013 .", "label": "", "metadata": {}, "score": "87.52449"}
{"text": "In addition to improving skeletal outcomes , denosumab has no requirement for renal monitoring and is administered as a simple subcutaneous injection . \"Study Results .", "label": "", "metadata": {}, "score": "87.651"}
{"text": "Osteonecrosis of the jaw ( ONJ ) was seen infrequently in both treatment groups ( 20 patients receiving denosumab ( 2.0 percent ) as compared with 14 patients ( 1.4 percent ) receiving Zometa ) .", "label": "", "metadata": {}, "score": "87.84087"}
{"text": "Osteonecrosis of the jaw ( ONJ ) was seen infrequently in both treatment groups ( 20 patients receiving denosumab ( 2.0 percent ) as compared with 14 patients ( 1.4 percent ) receiving Zometa ) .", "label": "", "metadata": {}, "score": "87.84087"}
{"text": "Osteonecrosis of the jaw ( ONJ ) was seen infrequently in both treatment groups ( 20 patients receiving denosumab ( 2.0 percent ) as compared with 14 patients ( 1.4 percent ) receiving Zometa ) .", "label": "", "metadata": {}, "score": "87.84087"}
{"text": "Osteonecrosis of the jaw ( ONJ ) was seen infrequently in both treatment groups ( 20 patients receiving denosumab ( 2.0 percent ) as compared with 14 patients ( 1.4 percent ) receiving Zometa ) .", "label": "", "metadata": {}, "score": "87.84087"}
{"text": "Published Results Show Amgen ( AMGN ) 's Denosumab Superior to Novartis Corporation ( NVS ) 's Zometa(R ) in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer .", "label": "", "metadata": {}, "score": "88.28492"}
{"text": "With a deep and broad pipeline of potential new medicines , Amgen remains committed to advancing science to dramatically improve people 's lives .This news release contains forward - looking statements that are based on management 's current expectations and beliefs and are subject to a number of risks , uncertainties and assumptions that could cause actual results to differ materially from those described .", "label": "", "metadata": {}, "score": "88.31854"}
{"text": "With a deep and broad pipeline of potential new medicines , Amgen remains committed to advancing science to dramatically improve people 's lives .This news release contains forward - looking statements that are based on management 's current expectations and beliefs and are subject to a number of risks , uncertainties and assumptions that could cause actual results to differ materially from those described .", "label": "", "metadata": {}, "score": "88.31854"}
{"text": "With a deep and broad pipeline of potential new medicines , Amgen remains committed to advancing science to dramatically improve people 's lives .This news release contains forward - looking statements that are based on management 's current expectations and beliefs and are subject to a number of risks , uncertainties and assumptions that could cause actual results to differ materially from those described .", "label": "", "metadata": {}, "score": "88.31854"}
{"text": "Osteonecrosis of the jaw ( ONJ ) was infrequent ( 22 patients receiving denosumab ( 2.3 percent ) as compared with 12 patients receiving Zometa ( 1.3 percent ) ) ; the incidence of ONJ was not significantly different between treatment arms .", "label": "", "metadata": {}, "score": "89.201965"}
{"text": "Both results were statistically significant .Overall , the incidence of adverse events and serious adverse events was consistent with what has previously been reported for these two agents .", "label": "", "metadata": {}, "score": "89.51937"}
{"text": "This broad and deep development program demonstrates Amgen 's commitment to researching and delivering pioneering medicines to patients with unmet medical needs .Amgen is studying denosumab in numerous tumor types across the spectrum of cancer induced bone disease .", "label": "", "metadata": {}, "score": "89.858025"}
{"text": "Please refer to Amgen 's most recent Forms 10-K , 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business .", "label": "", "metadata": {}, "score": "89.85922"}
{"text": "Please refer to Amgen 's most recent Forms 10-K , 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business .", "label": "", "metadata": {}, "score": "89.85922"}
{"text": "This broad and deep development program demonstrates Amgen 's commitment to researching and delivering pioneering medicines to patients with unmet medical needs .Amgen is studying denosumab in numerous tumor types across the spectrum of cancer - induced bone disease .", "label": "", "metadata": {}, "score": "89.91019"}
{"text": "This broad and deep development program demonstrates Amgen 's commitment to researching and delivering pioneering medicines to patients with unmet medical needs .Amgen is studying denosumab in numerous tumor types across the spectrum of cancer - induced bone disease .", "label": "", "metadata": {}, "score": "89.91019"}
{"text": "The data was analyzed from three large multi - center , randomized pivotal trials of more than 3,000 patients The trials demonstrate that the benefits of Zometa were maintained over the approximately two years of treatment follow - up .", "label": "", "metadata": {}, "score": "89.97562"}
{"text": "Our stock price may be affected by actual or perceived market opportunity , competitive position , and success or failure of our products or product candidates .", "label": "", "metadata": {}, "score": "90.41458"}
{"text": "Our stock price may be affected by actual or perceived market opportunity , competitive position , and success or failure of our products or product candidates .", "label": "", "metadata": {}, "score": "90.41458"}
{"text": "Our stock price may be affected by actual or perceived market opportunity , competitive position , and success or failure of our products or product candidates .", "label": "", "metadata": {}, "score": "90.41458"}
{"text": "Our stock price may be affected by actual or perceived market opportunity , competitive position , and success or failure of our products or product candidates .", "label": "", "metadata": {}, "score": "90.41458"}
{"text": "Our stock price may be affected by actual or perceived market opportunity , competitive position , and success or failure of our products or product candidates .", "label": "", "metadata": {}, "score": "90.41458"}
{"text": "Our stock price may be affected by actual or perceived market opportunity , competitive position , and success or failure of our products or product candidates .", "label": "", "metadata": {}, "score": "90.41458"}
{"text": "Punglia et al .[21 ] reported that as improving systemic therapy , local therapy got survival benefit dramatically .Niibe and Hayakawa [ 9 ] also reported the significance of systemic therapy for oligometastases and oligo - recurrence treated by local therapy .", "label": "", "metadata": {}, "score": "90.574905"}
{"text": "The Prolia trade name may not apply for future indications of denosumab .Denosumab is currently under global regulatory review for the reduction of SREs in patients with advanced cancer .", "label": "", "metadata": {}, "score": "90.58667"}
{"text": "The Prolia trade name may not apply for future indications of denosumab .Denosumab is currently under global regulatory review for the reduction of SREs in patients with advanced cancer .", "label": "", "metadata": {}, "score": "90.58667"}
{"text": "This broad and deep development program demonstrates Amgen 's commitment to researching and delivering pioneering medicines to patients with unmet medical needs .Amgen is studying denosumab in numerous tumor types across the spectrum of cancer - related bone diseases .", "label": "", "metadata": {}, "score": "90.616905"}
{"text": "This broad and deep development program demonstrates Amgen 's commitment to researching and delivering pioneering medicines to patients with unmet medical needs .Amgen is studying denosumab in numerous tumor types across the spectrum of cancer - related bone diseases .", "label": "", "metadata": {}, "score": "90.616905"}
{"text": "This broad and deep development program demonstrates Amgen 's commitment to researching and delivering pioneering medicines to patients with unmet medical needs .Amgen is studying denosumab in numerous tumor types across the spectrum of cancer - related bone diseases .", "label": "", "metadata": {}, "score": "90.616905"}
{"text": "\" Denosumab showed superior efficacy in preventing skeletal complications , and was generally well tolerated .These results in conjunction with the convenient subcutaneous dosing and without the need for renal monitoring , show that denosumab has the potential to be a meaningful advance over current treatments . \"", "label": "", "metadata": {}, "score": "90.75877"}
{"text": "Further , the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration ( FDA ) for the products .", "label": "", "metadata": {}, "score": "90.76535"}
{"text": "The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration ( FDA ) for the products .", "label": "", "metadata": {}, "score": "90.864914"}
{"text": "The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration ( FDA ) for the products .", "label": "", "metadata": {}, "score": "90.864914"}
{"text": "The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration ( FDA ) for the products .", "label": "", "metadata": {}, "score": "90.864914"}
{"text": "The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration ( FDA ) for the products .", "label": "", "metadata": {}, "score": "90.864914"}
{"text": "The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration ( FDA ) for the products .", "label": "", "metadata": {}, "score": "90.864914"}
{"text": "The incidence of adverse events ( AEs ) ( 96 percent denosumab , 97 percent Zometa ) and serious AEs ( 44 percent denosumab , 46 percent Zometa ) was consistent with what has previously been reported for these two agents .", "label": "", "metadata": {}, "score": "90.973694"}
{"text": "The incidence of adverse events ( AEs ) ( 96 percent denosumab , 97 percent Zometa ) and serious AEs ( 44 percent denosumab , 46 percent Zometa ) was consistent with what has previously been reported for these two agents .", "label": "", "metadata": {}, "score": "90.973694"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. T. Milano , A. W. Katz , M. C. Schell , A. Philip , and P. Okunieff , \" Descriptive analysis of oligometastatic lesions treated with curative - intent stereotactic body radiotherapy , \" International Journal of Radiation Oncology Biology Physics , vol .", "label": "", "metadata": {}, "score": "91.16136"}
{"text": "We develop product candidates internally and through licensing collaborations , partnerships and joint ventures .Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship .", "label": "", "metadata": {}, "score": "91.25582"}
{"text": "We develop product candidates internally and through licensing collaborations , partnerships and joint ventures .Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship .", "label": "", "metadata": {}, "score": "91.25582"}
{"text": "We develop product candidates internally and through licensing collaborations , partnerships and joint ventures .Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship .", "label": "", "metadata": {}, "score": "91.25582"}
{"text": "We develop product candidates internally and through licensing collaborations , partnerships and joint ventures .Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship .", "label": "", "metadata": {}, "score": "91.25582"}
{"text": "With a deep and broad pipeline of potential new medicines , Amgen remains committed to advancing science to dramatically improve people 's lives .Forward - Looking StatementsThis news release contains forward - looking statements that are based on management 's current expectations and beliefs and are subject to a number of risks , uncertainties and assumptions that could cause actual results to differ materially from those described .", "label": "", "metadata": {}, "score": "91.56377"}
{"text": "Overall , the incidence of adverse events ( 96 percent denosumab , 97 percent Zometa ) and serious adverse events ( 44 percent denosumab , 46 percent Zometa ) was consistent with what has previously been reported for these two agents .", "label": "", "metadata": {}, "score": "91.70447"}
{"text": "Overall , the incidence of adverse events ( 96 percent denosumab , 97 percent Zometa ) and serious adverse events ( 44 percent denosumab , 46 percent Zometa ) was consistent with what has previously been reported for these two agents .", "label": "", "metadata": {}, "score": "91.70447"}
{"text": "Hypocalcemia occurred more frequently with denosumab .No AEs of hypocalcemia were reported as fatal , and grade 3 or 4 AEs of hypocalcemia were similar between groups ( 1.6 percent denosumab , 1.2 percent zoledronic acid ) .", "label": "", "metadata": {}, "score": "91.81743"}
{"text": "Hypocalcemia occurred more frequently with denosumab .No AEs of hypocalcemia were reported as fatal , and grade 3 or 4 AEs of hypocalcemia were similar between groups ( 1.6 percent denosumab , 1.2 percent zoledronic acid ) .", "label": "", "metadata": {}, "score": "91.81743"}
{"text": "Support Care Cancer .( vi ) Norgaard M , Jensen AO , Jacobsen JB , Cetin K , Fryzek JP , Sorensen HT .Skeletal related events , bone metastasis and survival of prostate cancer : a population based cohort study in Denmark ( 1999 to 2007 ) .", "label": "", "metadata": {}, "score": "92.20276"}
{"text": "Support Care Cancer .( vi ) Norgaard M , Jensen AO , Jacobsen JB , Cetin K , Fryzek JP , Sorensen HT .Skeletal related events , bone metastasis and survival of prostate cancer : a population based cohort study in Denmark ( 1999 to 2007 ) .", "label": "", "metadata": {}, "score": "92.20276"}
{"text": "The scientific information discussed in this news release related to our product candidates is preliminary and investigative .Such product candidates are not approved by the U.S. Food and Drug Administration ( FDA ) , and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates .", "label": "", "metadata": {}, "score": "92.82466"}
{"text": "The most common AEs for denosumab were anemia , back pain , and nausea , and the most common AEs for Zometa were anemia , back pain , and decreased appetite .", "label": "", "metadata": {}, "score": "93.04964"}
{"text": "( 1 ) Diel IJ .Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease : A review .", "label": "", "metadata": {}, "score": "93.33341"}
{"text": "( 1 ) Diel IJ .Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease : A review .", "label": "", "metadata": {}, "score": "93.33341"}
{"text": "Denosumab demonstrated superiority over Zometa for both delaying the time to the first on - study SRE and reducing the rate of multiple SREs .Overall rates of adverse events and serious adverse events , including infections , were generally similar between the two arms .", "label": "", "metadata": {}, "score": "93.44792"}
{"text": "Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship .", "label": "", "metadata": {}, "score": "93.91205"}
{"text": "Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship .", "label": "", "metadata": {}, "score": "93.91205"}
{"text": "( Date:2/12/2016 ) ...12 , 2016 Sequent Medical , Inc. announced today that ... evaluate the safety and effectiveness of the WEB \u2122 Aneurysm ... intracranial aneurysms .", "label": "", "metadata": {}, "score": "94.320526"}
{"text": "Unless otherwise noted , Amgen is providing this information as of Nov. 8 , 2010 and expressly disclaims any duty to update information contained in this news release .", "label": "", "metadata": {}, "score": "94.95101"}
{"text": "The subjects were randomized to receive either 120 mg of denosumab subcutaneously every four weeks ( Q4W ) or Zometa administered intravenously at a dose of 4 mg single , 15 minute infusions every four weeks .", "label": "", "metadata": {}, "score": "95.54445"}
{"text": "In addition , we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products .", "label": "", "metadata": {}, "score": "95.67815"}
{"text": "In addition , we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products .", "label": "", "metadata": {}, "score": "95.67815"}
{"text": "In addition , we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products .", "label": "", "metadata": {}, "score": "95.67815"}
{"text": "In addition , we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products .", "label": "", "metadata": {}, "score": "95.67815"}
{"text": "In addition , we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products .", "label": "", "metadata": {}, "score": "95.67815"}
{"text": "In addition , we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products .", "label": "", "metadata": {}, "score": "95.67815"}
{"text": "With a deep and broad pipeline of potential new medicines , Amgen remains committed to advancing science to dramatically improve people 's lives .Forward - Looking Statements .", "label": "", "metadata": {}, "score": "96.44444"}
{"text": "With a deep and broad pipeline of potential new medicines , Amgen remains committed to advancing science to dramatically improve people 's lives .Forward - Looking Statements .", "label": "", "metadata": {}, "score": "96.44444"}
{"text": "It ... market size , as well as regional market drivers and ... discusses market penetration and market attractiveness , both for digital ... .Las Vegas ... fans .", "label": "", "metadata": {}, "score": "96.85257"}
{"text": "2002 Aug;2(8):584 - 93 .( Date:2/4/2016 ) ... ...February 04 , 2016 , ... Morf Media Inc ... an interactive FDA compliance training course , Writing Effective SOPs ... accredited interactive course on Morf Playbook - now conveniently available on smartphones and PCs -- provides step ... .", "label": "", "metadata": {}, "score": "97.22062"}
{"text": "( 2 ) Coleman , R. Potential use of bisphosphonates in the prevention of metastases in early - stage breast cancer .Clin Breast Cancer .", "label": "", "metadata": {}, "score": "97.253876"}
{"text": "( 2 ) Coleman , R. Potential use of bisphosphonates in the prevention of metastases in early - stage breast cancer .Clin Breast Cancer .", "label": "", "metadata": {}, "score": "97.253876"}
{"text": "Detailed Description .Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 3 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator )", "label": "", "metadata": {}, "score": "97.83722"}
{"text": "Experimental : Zoledronic acid q 12 weeks .Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind .", "label": "", "metadata": {}, "score": "98.0338"}
{"text": "Unless otherwise noted , Amgen is providing this information as of Sept. 22 , 2009 and expressly disclaims any duty to update information contained in this news release .", "label": "", "metadata": {}, "score": "98.35732"}
{"text": "Unless otherwise noted , Amgen is providing this information as of Sept. 22 , 2009 and expressly disclaims any duty to update information contained in this news release .", "label": "", "metadata": {}, "score": "98.35732"}
{"text": "Webcast Information .Amgen will hold an analyst / investor event at a local venue in Chicago on Monday , June 7 at 7:30 p.m. Central Time to discuss data presented at ASCO .", "label": "", "metadata": {}, "score": "98.35949"}
{"text": "Unless otherwise noted , Amgen is providing this information as of July 7 , 2009 and expressly disclaims any duty to update information contained in this news release .", "label": "", "metadata": {}, "score": "98.50758"}
{"text": "An analyst / investor event will also be held from the Congress on September 24th , at 6:30 a.m. Eastern Time to discuss data presented at ECCO - ESMO .", "label": "", "metadata": {}, "score": "98.59912"}
{"text": "An analyst / investor event will also be held from the Congress on September 24th , at 6:30 a.m. Eastern Time to discuss data presented at ECCO - ESMO .", "label": "", "metadata": {}, "score": "98.59912"}
{"text": "( xiii ) .About Denosumab and Amgen 's Research in Bone BiologyDenosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand , the essential regulator of osteoclasts ( the cells that break down bone ) .", "label": "", "metadata": {}, "score": "99.372314"}
{"text": "( Date:2/11/2016 ) ... , February 11 , 2016 ... at Worldwide Clinical Trials , will present at this year , s Summit ... the Hyatt Regency in Miami , FL . ... partnerships to optimize study execution , supporting SCOPE , s \" Improving Site Study ... take place on Thursday , Feb. 25 at 11:05 a.m. ... .", "label": "", "metadata": {}, "score": "101.082886"}
{"text": "THOUSAND OAKS Calif. Nov. 8 2010 /- Amgen ( N ..Patients with bone metastases from cancer are at increased risk of ex ...Study ResultsIn the study denosumab was superior to Zometa in dela ...", "label": "", "metadata": {}, "score": "101.54307"}
{"text": "Experimental : Zoledronic acid every ( q ) 4 weeks .Participants received 4 mg of zoledronic acid intravenously ( IV ) infusion q 4 weeks .", "label": "", "metadata": {}, "score": "101.79459"}
{"text": "MedPageToday is a trusted and reliable source for clinical and policy coverage that directly affects the lives and practices of health care professionals .Physicians and other healthcare professionals may also receive Continuing Medical Education ( CME ) and Continuing Education ( CE ) credits at no cost for participating in MedPage Today - mptabsoluteurled educational activities .", "label": "", "metadata": {}, "score": "103.40933"}
{"text": "2002 Aug;2(8):584 - 93 .( Date:2/9/2016 ) ... , February 9 , 2016 ... replace paper and protect IP E - WorkBook 10 ... be rolled out in Germany early ... protect valuable IP .", "label": "", "metadata": {}, "score": "103.99164"}
{"text": "The ... new behaviors and create new habits .The workshops cover a broad range of ... .", "label": "", "metadata": {}, "score": "104.27673"}
{"text": "l .u .e . was used to determine the level of statistical significance .Analyses were performed with Stata version 11 for Windows ( Stata , Chicago , IL , USA ) .", "label": "", "metadata": {}, "score": "104.45731"}
{"text": "( xiii ) .About Denosumab and Amgen 's Research in Bone Biology .Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand , the essential regulator of osteoclasts ( the cells that break down bone ) .", "label": "", "metadata": {}, "score": "105.031876"}
{"text": "Drug : Zoledronic acid .4 mg IV .Other Names : .Zoledronate .ZOL446 .Zometa .Drug : Placebo .Placebo to zoledronic acid .", "label": "", "metadata": {}, "score": "106.91469"}
{"text": "Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand , the essential regulator of osteoclasts ( the cells that break down bone ) .", "label": "", "metadata": {}, "score": "107.26416"}
{"text": "Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand , the essential regulator of osteoclasts ( the cells that break down bone ) .", "label": "", "metadata": {}, "score": "107.26416"}
{"text": "Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand , the essential regulator of osteoclasts ( the cells that break down bone ) .", "label": "", "metadata": {}, "score": "107.26416"}
{"text": "Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand , the essential regulator of osteoclasts ( the cells that break down bone ) .", "label": "", "metadata": {}, "score": "107.26416"}
{"text": "2016 BioElectronics Corporation ( OTC Pink : BIEL ) , the ... that it is responding to a notice of ... and Exchange Commission posted on the agency website . ... the Board of BioElectronics Corporation and the Edward ...", "label": "", "metadata": {}, "score": "107.3087"}
{"text": "LIVERMORE , Calif. , Feb. 3 , 2016 ... Police Department in Missouri ... of license plate reader ( LPR ) data from Vigilant Solutions . ... a hit - and - run case in which the victim was walking out ... a parking space next to his vehicle , striking his ... .", "label": "", "metadata": {}, "score": "108.79228"}
{"text": "Paris , France and Principal Investigator of the ... France and Germany .Although patients with ruptured ... .( Date:2/12/2016 ) ...12 , 2016 Eli Lilly and Company ( NYSE : LLY ...", "label": "", "metadata": {}, "score": "109.117645"}
{"text": "According to Publisher ... a Buddhist teacher for teaching and helping others .Valentine 's Day celebrates love in ... .( Date:2/12/2016 ) ...( PRWEB ) , ... February 12 , 2016 , ... ...", "label": "", "metadata": {}, "score": "109.606186"}
{"text": "France , Italy and ... product only with dextrose solution .( Date:2/13/2016 ) ... ... 13 , 2016 , ... Christie Medical Holdings , Inc. presented the ...", "label": "", "metadata": {}, "score": "110.003876"}
{"text": "This ... draw blood , combining technology with traditional technique . , \" VeinViewer is a wonderful new ... .( Date:2/12/2016 ) ... ...February 12 , 2016 , ...", "label": "", "metadata": {}, "score": "113.09987"}
{"text": "CONTACT : Amgen , Thousand OaksChristine Regan :+1 ( 805 ) 447 - 5476 ( media)Arvind Sood :+1 ( 805 ) 447 - 1060 ( investors)(i ) Coleman RE .", "label": "", "metadata": {}, "score": "114.08769"}
{"text": "( Date:2/12/2016 ) ... , ... February 12 , 2016 , ... Dignity Health named ...Hospital Emergency Room -Mesa .The new facility is licensed under Dignity Health ... \" Dr. Bingham is an excellent leader and will ensure our new freestanding emergency room ... .", "label": "", "metadata": {}, "score": "114.90047"}
{"text": "303 - 310 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus Current Secondary Outcome Measures ICMJE ( submitted : August 18 , 2014 ) .", "label": "", "metadata": {}, "score": "115.90963"}
{"text": "66 , no .5 , pp . 1366- 1369 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y.", "label": "", "metadata": {}, "score": "124.70717"}
{"text": "52 , no . 2 , pp .101 - 109 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y.", "label": "", "metadata": {}, "score": "125.014175"}
{"text": "All rights reserved .The material on this site is for informational purposes only , and is not a substitute for medical advice , diagnosis or treatment provided by a qualified health care provider .", "label": "", "metadata": {}, "score": "129.1619"}
{"text": "( Date:2/8/2016 ) ... active R&D program for the development of future natural products ... unique research and development center in Israel ...Stockton has a variety of products ... is active in more than 35 counties worldwide . ... flagship product Timorex Gold \u00ae is used to ... .", "label": "", "metadata": {}, "score": "139.5462"}
{"text": "Received 17 May 2012 ; Revised 8 July 2012 ; Accepted 9 July 2012 .Academic Editor : Hideomi Yamashita .Copyright \u00a9 2012 Ken - ichi Tabata et al .", "label": "", "metadata": {}, "score": "146.18112"}
